The stock of St. Jude Medical, Inc. (NYSE:STJ) is a huge mover today! About 752,638 shares traded hands. St. Jude Medical, Inc. (NYSE:STJ) has risen 43.63% since March 9, 2016 and is uptrending. It has outperformed by 36.22% the S&P500.
The move comes after 6 months positive chart setup for the $21.57 billion company. It was reported on Oct, 12 by Barchart.com. We have $125.57 PT which if reached, will make NYSE:STJ worth $12.94B more.
Analysts await St. Jude Medical, Inc. (NYSE:STJ) to report earnings on October, 19. They expect $1.01 EPS, up 4.12% or $0.04 from last year’s $0.97 per share. STJ’s profit will be $277.60M for 19.43 P/E if the $1.01 EPS becomes a reality. After $1.06 actual EPS reported by St. Jude Medical, Inc. for the previous quarter, Wall Street now forecasts -4.72% negative EPS growth.
St. Jude Medical, Inc. (NYSE:STJ) Ratings Coverage
Out of 20 analysts covering St. Jude Medical Inc. (NYSE:STJ), 4 rate it a “Buy”, 0 “Sell”, while 16 “Hold”. This means 20% are positive. St. Jude Medical Inc. has been the topic of 45 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Sector Perform” rating given on Thursday, October 22 by RBC Capital Markets. The company was initiated on Tuesday, September 22 by UBS. Oppenheimer maintained it with “Perform” rating and $64 target price in Thursday, January 28 report. As per Tuesday, May 10, the company rating was downgraded by SunTrust. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Buy” rating given on Sunday, August 9 by BTIG Research. Nomura initiated St. Jude Medical, Inc. (NYSE:STJ) on Thursday, March 17 with “Buy” rating. The rating was downgraded by Suntrust Robinson on Tuesday, May 10 to “Neutral”. The stock has “Buy” rating given by Suntrust Robinson on Friday, January 8. As per Tuesday, September 1, the company rating was maintained by Evercore. The firm has “Buy” rating by SunTrust given on Friday, January 8.
According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.13, from 0.99 in 2016Q1. The ratio fall, as 73 funds sold all St. Jude Medical, Inc. shares owned while 218 reduced positions. 108 funds bought stakes while 143 increased positions. They now own 256.31 million shares or 7.42% more from 238.60 million shares in 2016Q1.
Moreover, Farmers Merchants Investments has 0% invested in St. Jude Medical, Inc. (NYSE:STJ) for 169 shares. Lmr Prtnrs Llp has invested 1.21% of its portfolio in St. Jude Medical, Inc. (NYSE:STJ). California Employees Retirement Sys accumulated 0.09% or 747,201 shares. Strs Ohio holds 6,727 shares or 0% of its portfolio. The Michigan-based Plante Moran Fincl has invested 0.02% in St. Jude Medical, Inc. (NYSE:STJ). Cornerstone Cap Management Ltd Liability Co holds 0.04% of its portfolio in St. Jude Medical, Inc. (NYSE:STJ) for 63,046 shares. Alexandria Limited Liability accumulated 65 shares or 0% of the stock. First Wilshire Securities has 0.13% invested in the company for 5,250 shares. Analytic Ltd Llc reported 9,256 shares or 0.01% of all its holdings. Pinnacle Associates holds 0.02% or 10,874 shares in its portfolio. Cambridge Invest Rech Advisors, a Iowa-based fund reported 16,071 shares. Millennium Mngmt Limited Liability Com holds 577,300 shares or 0.1% of its portfolio. Vanguard Grp Incorporated holds 0.08% of its portfolio in St. Jude Medical, Inc. (NYSE:STJ) for 16.71M shares. Royal London Asset Mgmt Limited holds 0.12% or 94,156 shares in its portfolio. John G Ullman Associate accumulated 85,534 shares or 1.37% of the stock.
More notable recent St. Jude Medical, Inc. (NYSE:STJ) news were published by: Wsj.com which released: “St. Jude Medical Warns of Battery Problems With Heart Products” on October 11, 2016, also Investorplace.com with their article: “3 Stocks to Watch Tuesday: Illumina, Inc. (ILMN), Seagate Technology PLC (STX …” published on October 11, 2016, Miamiherald.com published: “Rent-A-Center, St. Jude Medical fall; Twilio, Tyson gain” on October 11, 2016. More interesting news about St. Jude Medical, Inc. (NYSE:STJ) were released by: Businesswire.com and their article: “St. Jude Medical Announces U.S. Launch and First Implant of New Deep Brain …” published on October 06, 2016 as well as Businesswire.com‘s news article titled: “St. Jude Medical Announces FDA Approval of BurstDR Stimulation, a New Superior …” with publication date: October 04, 2016.
STJ Company Profile
St. Jude Medical, Inc., incorporated on May 12, 1976, is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator (ICD) systems; atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker (pacemaker) systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders), and Thoratec products (ventricular assist devices and percutaneous heart pumps).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.